Arjun Balar, MD, Oncology, New York, NY, NYU Langone Hospitals

ArjunVasantBalarMD

Oncology New York, NY

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Medicine, New York University School of Medicine; Director - Genitourinary Medical Oncology Program, Perlmutter Cancer Center at NYU Langone Health

Overview of Dr. Balar

Dr. Arjun Balar is an oncologist in New York, NY and is affiliated with NYU Langone Hospitals. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 11 years. He is one of 121 doctors at NYU Langone Hospitals who specialize in Oncology.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFELLOWSHIP
  • New York Presbyterian Hospital
    New York Presbyterian HospitalRESIDENCY
  • University of South Florida Morsani College of Medicine
    University of South Florida Morsani College of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2008 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 stu... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC
    Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBCMay 29, 2020
  • A New Era in Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
    A New Era in Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar
  • Expert Discusses Promising Data with Pembrolizumab for Unmet Need in NMIBC
    Expert Discusses Promising Data with Pembrolizumab for Unmet Need in NMIBCMay 23, 2019
  • Join now to see all

Hospital Affiliations